AbbVie (TICKER: ABBV) Benchmark And Performance Data

there are 10 of samples in the benchmark for AbbVie in year 2022 in 2022. The total inventory for AbbVie was $3,310,000,000.00 in 2020. The total inventory for AbbVie was $3,128,000,000.00 in 2021. The total inventory for AbbVie was $1,813,000,000.00 in 2019. The total inventory for AbbVie was $1,719,000,000.00 in 2015. The total inventory for AbbVie was $1,605,000,000.00 in 2018. The total inventory for AbbVie was $1,605,000,000.00 in 2017. The total inventory for AbbVie was $1,444,000,000.00 in 2016. The total inventory for AbbVie was $1,150,000,000.00 in 2013. The total inventory for AbbVie was $1,124,000,000.00 in 2014. The total inventory for AbbVie was $1,091,000,000.00 in 2012. The sales, general, and administrative (SGA) for AbbVie was $7,724,000,000.00 in 2014. The sales, general, and administrative (SGA) for AbbVie was $7,399,000,000.00 in 2018. The sales, general, and administrative (SGA) for AbbVie was $6,942,000,000.00 in 2019. The sales, general, and administrative (SGA) for AbbVie was $6,387,000,000.00 in 2015. The sales, general, and administrative (SGA) for AbbVie was $6,295,000,000.00 in 2017. The sales, general, and administrative (SGA) for AbbVie was $5,881,000,000.00 in 2016. The sales, general, and administrative (SGA) for AbbVie was $5,352,000,000.00 in 2013. The sales, general, and administrative (SGA) for AbbVie was $4,989,000,000.00 in 2012. The sales, general, and administrative (SGA) for AbbVie was $12,349,000,000.00 in 2021. The sales, general, and administrative (SGA) for AbbVie was $11,299,000,000.00 in 2020. The sales, general, and administrative (SGA) for AbbVie was $$15,260,000,000 in 2022. The revenue volatility for AbbVie was 23.90% in 2022. The market capitalization for AbbVie was $286,427,779,598.00 in 2015. The market capitalization for AbbVie was $285,804,134,897.00 in 2018. The market capitalization for AbbVie was $281,123,738,255.00 in 2019. The market capitalization for AbbVie was $270,790,961,867.00 in 2016. The market capitalization for AbbVie was $263,097,858,120.00 in 2021. The market capitalization for AbbVie was $239,432,924,038.00 in 2014. The market capitalization for AbbVie was $237,771,363,746.00 in 2020. The market capitalization for AbbVie was $237,337,087,607.00 in 2017. The market capitalization for AbbVie was $199,037,757,952.00 in 2012. The market capitalization for AbbVie was $190,693,329,440.00 in 2013. The market capitalization for AbbVie was $$297,793,000,000 in 2022. The gross revenue for AbbVie was $56,197,000,000.00 in 2021. The gross revenue for AbbVie was $45,804,000,000.00 in 2020. The gross revenue for AbbVie was $33,266,000,000.00 in 2019. The gross revenue for AbbVie was $32,753,000,000.00 in 2018. The gross revenue for AbbVie was $28,216,000,000.00 in 2017. The gross revenue for AbbVie was $25,638,000,000.00 in 2016. The gross revenue for AbbVie was $22,859,000,000.00 in 2015. The gross revenue for AbbVie was $19,960,000,000.00 in 2014. The gross revenue for AbbVie was $18,790,000,000.00 in 2013. The gross revenue for AbbVie was $18,380,000,000.00 in 2012. The gross revenue for AbbVie was $$58,054,000,000 in 2022. The gross margin for AbbVie was $32.41% in 2022. The days sales outstanding for AbbVie was 67 days in 2022. The days payable outstanding for AbbVie was 61 days in 2022. The days of inventory for AbbVie was $70 in 2022. The cost of goods sold (COGS) for AbbVie was 30.00% in 2022. The cost of goods sold (COGS) for AbbVie was $7,718,000,000.00 in 2018. The cost of goods sold (COGS) for AbbVie was $7,439,000,000.00 in 2019. The cost of goods sold (COGS) for AbbVie was $7,042,000,000.00 in 2017. The cost of goods sold (COGS) for AbbVie was $5,832,000,000.00 in 2016. The cost of goods sold (COGS) for AbbVie was $4,581,000,000.00 in 2013. The cost of goods sold (COGS) for AbbVie was $4,508,000,000.00 in 2012. The cost of goods sold (COGS) for AbbVie was $4,500,000,000.00 in 2015. The cost of goods sold (COGS) for AbbVie was $4,426,000,000.00 in 2014. The cost of goods sold (COGS) for AbbVie was $17,446,000,000.00 in 2021. The cost of goods sold (COGS) for AbbVie was $15,387,000,000.00 in 2020. The cost of goods sold (COGS) for AbbVie was $$17,414,000,000 in 2022. The cash to cash cycle time for AbbVie was 76 in 2022. The annual percentage growth rate of AbbVie was -0.03% in 2022. AbbVie in its benchmark peer group, had rank 8 for sales growth in 2022. AbbVie in its benchmark peer group, had rank 7 for cost of goods sold as a percent of revenue in 2022. AbbVie in its benchmark peer group, had rank 6 days for days sales outstanding in 2022. AbbVie in its benchmark peer group, had rank 5 for cash to cash cycle time in 2022. AbbVie in its benchmark peer group, had rank 4 for gross revenue in 2022. AbbVie in its benchmark peer group, had rank 1 days for days of inventory in 2022. AbbVie headquarters region is Central. AbbVie has ticker symbol ABBV. AbbVie has the following profile: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.. AbbVie has primary indstury Drug Manufacturers - General. AbbVie had a $$37,428,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. AbbVie had Organon, and Eli Lilly, and AbbVie, and Pfizer, and Bristol-Myers Squibb, and Amgen, and Gilead Sciences, and Biogen, and Johnson & Johnson, and Merck benchmark peer companies for its SIC code in 2022. AbbVie had 9.55% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. AbbVie had 8 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. AbbVie had 6 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. AbbVie had 50,000 number of employees in 2022. AbbVie had 3.14% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. AbbVie had 1.18% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. AbbVie had 0.02% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. AbbVie had 0 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. AbbVie can reduce overall cost by $$4,878,000,000 by improving both COGS and SGA to next benchmark tier in 2022. AbbVie can reduce inventory with practices including in 2022. AbbVie can reduce days sales outstanding with practices including in 2022. AbbVie can increase sales revenue by $$37,428,000,000 improving sales performance to next benchmark tier in 2022. AbbVie can increase revenue growth by $$13,000,000 by improving growth performance to next benchmark tier in 2022. AbbVie can increase overall revenue by $$37,441,000,000 by improving both growth and sales performance to next benchmark tier in 2022. AbbVie can increase days payables outstanding with practices including Strategic Sourcing in 2022. AbbVie can increase days payables outstanding by $4,613,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. AbbVie can improve total financial performance by $$47,822,000,000 by improving revenue, costs, and working capital in 2022. AbbVie can decrease overall working capital by $$5,503,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. AbbVie can decrease inventory days by $0 days by reducing inventory days to next benchmark tier in 2022. AbbVie can decrease days sales outstanding by $891,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. AbbVie can accelerate revenue growth practices including Revenue-optimized Planning in 2022. AbbVie can accelerate revenue growth practices including Pricing Optimization in 2022. AbbVie can accelerate revenue growth practices including Accelerate Design Pipeline in 2022. 82 days was the measured parity or middle performance level for cash to cash cycle time in AbbVie's peer group in 2022. 79 days was the measured superior or top ten performance level for days of inventory in AbbVie's peer group in 2022. 68 days was the measured advantage or top third performance level for cash to cash cycle time in AbbVie's peer group in 2022. 66 days was the measured parity or middle performance level for days sales outstanding in AbbVie's peer group in 2022. 61 days was the measured advantage or top third performance level for days sales outstanding in AbbVie's peer group in 2022. 6.73% was the measured superior or top ten performance level for sales volatility in AbbVie's peer group in 2022. 56 days was the measured superior or top ten performance level for days sales outstanding in AbbVie's peer group in 2022. 37.46% was the measured superior or top ten performance level for gross margin in AbbVie's peer group in 2022. 37 days was the measured superior or top ten performance level for cash to cash cycle time in AbbVie's peer group in 2022. 26.85% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in AbbVie's peer group in 2022. 22.98% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in AbbVie's peer group in 2022. 21.84% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in AbbVie's peer group in 2022. 14.35% was the measured parity or middle performance level for sales volatility in AbbVie's peer group in 2022. 129 days was the measured parity or middle performance level for days of inventory in AbbVie's peer group in 2022. 100 days was the measured advantage or top third performance level for days of inventory in AbbVie's peer group in 2022. 10.93% was the measured advantage or top third performance level for sales volatility in AbbVie's peer group in 2022. 0.03% was the measured superior or top ten performance level for sales growth in AbbVie's peer group in 2022. 0.00% was the measured advantage or top third performance level for sales growth in AbbVie's peer group in 2022. -0.01% was the measured parity or middle performance level for sales growth in AbbVie's peer group in 2022. $33.59% was the measured advantage or top third performance level for gross margin in AbbVie's peer group in 2022. $30.58% was the measured parity or middle performance level for gross margin in AbbVie's peer group in 2022. $$95,482,000,000 was the measured superior or top ten performance level for gross revenue in AbbVie's peer group in 2022. $$58,423,000,000 was the measured advantage or top third performance level for gross revenue in AbbVie's peer group. $$37,350,000,000 was the measured parity or middle performance level for gross revenue in AbbVie's peer group in 2022.